131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)

Summary

This is an open label, single arm, parallel-group, multicentre, and dose finding study to evaluate the safety of ascending radioactive dose levels of 131I-TLX101 administered intravenously in combination with best standard of care in newly diagnosed GBM patients.

Timeline

Start

2023-04-01

Primary completion

2026-06

Completion

2026-06

Drugs

Indications